Gold prices hold sharp gains as soft US jobs data fuels Fed rate cut bets
LONDON - Physiomics plc (AIM: PYC), a company specializing in mathematical modelling and biostatistics, has announced the publication of a joint research study with Ankyra Therapeutics in the Journal of Molecular Cancer Therapeutics, a peer-reviewed journal of the American Association for Cancer Research. The study, focused on a pharmacokinetic and pharmacodynamic model for an interleukin-12 anchored-drug conjugate aimed at treating solid tumors, showcases the application of mathematical models in drug development.
The research details how Physiomics assisted Ankyra Therapeutics in understanding the mechanism of action and optimal dosing schedule for their drug candidate, ANK-101. The insights gained from the study have been instrumental in advancing the drug into clinical trials, with the design of a phase 1 trial being informed by these findings.
Dr. Peter Sargent, CEO of Physiomics, highlighted the significance of this publication as the third within a three-month period, demonstrating the impact of the company’s expertise on drug development programs. He also emphasized the increasing importance of mathematical modelling in the pharmaceutical industry, driven by regulatory demands for such methods in the drug approval process.
The collaboration between Physiomics and Ankyra Therapeutics exemplifies the growing trend of integrating data science and advanced computational techniques in the development of new therapeutics. The publication of their joint research underscores the potential benefits of this approach in enhancing the efficiency and effectiveness of drug development strategies.
The study’s publication is based on a press release statement from Physiomics plc and reflects the company’s position in the market as a provider of mathematical modelling services for the pharmaceutical industry. The research is accessible online through the Journal of Molecular Cancer Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.